Table 1.
Baseline characteristics of the study groups based on their eGFR
| eGFR >60 ml·min−1·1.73 m−2 HALT-A | eGFR 25–60 ml·min−1·1.73 m−2 HALT-B | |
|---|---|---|
| Age, yr | 37.0 ± 7.8 | 47.1 ± 8.0† |
| Male, % | 60.7 | 50.0 |
| Systolic BP, mmHg | 127.5 ± 13.0 | 132.0 ± 12.8 |
| Diastolic BP, mmHg | 74.5 ± 13.2 | 78.0 ± 9.6 |
| eGFR, ml·min−1·1.73 m−2 | 82.4 ± 17.7 | 48.2 ± 8.4† |
| Urine creatinine, mg/ml | 0.7 ± 0.4 | 0.6 ± 0.3* |
| Serum creatinine, mg/dl | 1.0 ± 0.2 | 1.5 ± 0.3† |
| Urine microalbumin, mg/day | 41.1 ± 93.0 | 53.1 ± 69.3 (n = 36) |
| BSA, m2 | 2.0 ± 0.3 | 2.0 ± 0.2 |
| LV mass, g | 127.2 ± 29.7 | ND |
| LVMI, g/m2 | 64.0 ± 13.5 | ND |
| TKV, ml | 1,365 ± 702 | ND |
| TKV/BSA, ml/m2 | 674 ± 333 | ND |
Values are means ± SD.
eGFR, estimated glomerular filtration rate; HALT, Halt Progression of Polycystic Kidney Disease study (HALT-A, early disease group; HALT-B, moderately advanced disease group); BP, blood pressure; BSA, body surface area; LV, left ventricular; TKV, total kidney volume; ND, not determined.
Samples from 18 healthy subjects were utilized for the study (10 males and 8 females; age 33.7 ± 9.2 yr, P < 0.001 vs. HALT-B). Significance levels:
*
P < 0.05,
†
P < 0.001 for HALT-A (eGFR >60 ml·min−1·1.73 m−2) vs. HALT-B (eGFR 25-60 ml·min−1·1.73 m−2 patients.